Samsung Bioepis Co., Ltd. aims to produce the best biopharmaceutical products with its highly proficient industry expertise and advanced technologies and ultimately contribute to the health and welfare of people. The company was established in 2012 as part of the Samsung group and its name “Samsung Bioepis” is the combination of the words “bio (life)” and “epistimi (science)”. Samsung Bioepis is strongly committed to creating affordable and quality biopharmaceutical products for all stages of life. Please visit www.samsungbioepis.com for more information.
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have…
Young-Woo Park, CEO of Y-Biologics – renowned for their library with diversity of 1011 – unveils their plan to be the first in Korea to develop the PD-1 antibody as…
Yong Zu Kim, founder and CEO of Lego Chem, discusses his company’s two areas of focus, anti-infectives and antibody drug conjugates. Dr Kim explains how his strategy has changed from…
Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune…
Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation…
Professor Jong In Lim, cyber security specialist and president of the Institute for Cyber Security and Privacy (ICSP) provides his assessment of the current situation for information security in Korea,…
Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of…
Hakhyun Nam, co-founder and CTO at i-SENS, Inc. a developer of glucose sensor devices, reveals his path to running a globally successful medical devices company, and how i-SENS overcame early…
Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for…
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
See our Cookie Privacy Policy Here
